TY  - JOUR
AU  - Bhattad, Venugopal B.
AU  - Gaddam, Sathvika
AU  - Lassiter, Margaret A.
AU  - Jagadish, Pooja S.
AU  - Ardeshna, Devarshi
AU  - Cave, Brandon
AU  - Khouzam, Rami N.
PY  - 2019
TI  - Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events
JF  - Annals of Translational Medicine; Vol 7, No 17 (September 11, 2019): Annals of Translational Medicine (Focus on: “Anticoagulation, Catheterization, and Minimizing Intervention: How Cutting-Edge Cuts Down Disease”)
Y2  - 2019
KW  - 
N2  - Cangrelor is a relatively new antiplatelet drug that has been approved for use as an adjunct therapy to percutaneous coronary intervention (PCI) to decrease peri-procedural myocardial infarction (MI), coronary revascularization, and stent thrombosis. Cangrelor is an adenosine triphosphate analogue with a pharmacokinetic mechanism based on a reversible, dose-dependent inhibition adenosine diphosphate (ADP)-induced platelet aggregation. This drug has lately been in the spotlight as a possible bridge therapy for anti-platelet medication prior to cardiac and non-cardiac surgeries. Platelet function is usually restored within sixty minutes of cessation of therapy, thereby decreasing the risk of bleeding while providing adequate pre-procedural coverage to reduce ischemic events. This manuscript reviews the literature on cangrelor and summarizes its role as a peri-procedural bridge.
UR  - https://atm.amegroups.org/article/view/28054